Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-099407
Filing Date
2025-07-29
Accepted
2025-07-29 08:39:01
Documents
81
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20250630.htm   iXBRL 10-Q 2672884
2 EX-31.1 fulc-ex31_1.htm EX-31.1 14136
3 EX-31.2 fulc-ex31_2.htm EX-31.2 14127
4 EX-32.1 fulc-ex32_1.htm EX-32.1 7998
5 EX-32.2 fulc-ex32_2.htm EX-32.2 7343
  Complete submission text file 0000950170-25-099407.txt   10089530

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fulc-20250630.xsd EX-101.SCH 1319277
83 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20250630_htm.xml XML 1842984
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 251157787
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)